Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions

  title={Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions},
  author={Matteo Repetto and Edoardo Crimini and Federica Giugliano and Stefania Morganti and Carmen Belli and Giuseppe Curigliano},
  journal={Expert Review of Clinical Pharmacology},
  pages={1233 - 1252}
ABSTRACT Introduction: Fibroblast growth factor receptor (FGFR)/fibroblast growth factor (FGF) is a pathway characterized by recurring alterations in cancer. Its dysregulations enhance cancer cell proliferation, survival, migration and invasion, as well as angiogenesis and immune evasion. Areas covered: FGFR/FGF selective inhibitors belong to a broad class of drugs with some being approved for specific indications and others under investigation in ongoing phase I and II clinical trials. In this… 

FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance

Treatment strategies based on FGF/FGFR inhibition (using receptor inhibitors, ligand traps, monoclonal antibodies, or microRNAs) appear to be extremely promising, however, this approach may lead to further development of resistance through acquisition of specific mutations, metabolism switching, and molecular cross-talks.

A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo

A novel specific FGFR inhibitor, RK-019, with potent anti-FGFR2-amp GC activity both in vitro and in vivo is reported.



Fibroblast growth factor receptors as treatment targets in clinical oncology

  • M. Katoh
  • Biology, Medicine
    Nature Reviews Clinical Oncology
  • 2018
The clinical experience with FGFR inhibitors to date is described, and key aspects that might lead to improved response rates and/or the avoidance of acquired resistance are highlighted, including the selection of patients who are most likely to benefit from treatment, and the use ofFGFR inhibitors in combination regimens with other agents.

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

Cell proliferation studies demonstrated ARQ 087 has anti-proliferative activity in cell lines driven by FGFR dysregulation, including amplifications, fusions, and mutations, and in vitro and in vivo activity against FGFR addicted cell lines and tumors.

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

Results indicate that inhibition of FGFR1 and wild-type or mutant FGFR3 may represent a useful therapeutic approach in patients with both non-muscle invasive and muscle invasive UC.

Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

This review summarizes the structure of FGFR, especially its kinase domain, and the development of small molecule FGFR inhibitors.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

The first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive ICC are reported, which can inform future strategies for detecting resistance mechanisms and inducing more durable remissions in ICC and in the wide variety of cancers where the FGFR pathway is being explored as a therapeutic target.

Targeting FGFR Signaling in Cancer

This review focuses on recent data from clinical trials evaluating FGFR targeting therapies and discusses the challenges and perspectives for the development of these agents.

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

This study evaluated mutation and expression status of FGFR3 in 19 urothelial cancer cell lines and a cohort of 170 American patients with bladder cancer and showed inhibitory activity of R3Mab on tumor growth and corresponding cell signaling in three different orthotopic xenografts of bladder cancer.

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.

It is reported that the irreversible pan-FGFR inhibitor, TAS-120, demonstrated efficacy in four patients with FGFR2-fusion-positive ICC who developed resistance to BGJ398 or Debio1347 and suggests that strategic sequencing of FGFR inhibitors, guided by serial biopsies and ctDNA, may prolong the duration of benefit from FGFR inhibition in patients withFGFR2 fusion- positive ICC.

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

The preclinical data presented for INCB054828, together with preliminary clinical observations, support continued investigation in patients with FGFR alterations, such as fusions and activating mutations, and suggest target inhibition is achievable by INCB 19054828 in vivo with low oral doses.

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

The results suggest that FGFR pathway is a distinct mechanism of acquired resistance to ER-directed therapy that can be overcome by FGFR and/or MAPK pathway inhibitors.